What is a solitary plasmacytoma?
A solitary plasmacytoma is a single tumour made of abnormal plasma cells. Plasma cells are white blood cells in the bone marrow that normally make antibodies to fight infection.
In multiple myeloma, abnormal plasma cells spread throughout the bone marrow. In a solitary plasmacytoma, they form just one lump, and tests of the rest of the bone marrow and skeleton are normal or nearly normal.
There are two main types:
- Solitary plasmacytoma of bone (SBP), which grows inside a bone, most often in the spine
- Solitary extramedullary plasmacytoma (SEP), which grows in soft tissue outside the bone, most often in the nose, sinuses or throat
The main treatment is radiotherapy, which controls the tumour in most people. However, many people with solitary plasmacytoma of bone later develop multiple myeloma, so lifelong follow-up is needed.
1. Key facts at a glance
| Feature | Details |
|---|---|
| How common | Rare; about 3-5% of plasma cell cancers |
| Typical age | Median about 55-65; younger on average than people with myeloma |
| Sex | About twice as common in men |
| Types | Bone (about two-thirds) and extramedullary (about one-third) |
| Common sites | Bone: spine, ribs, pelvis, skull, long bones. Extramedullary: nasal cavity, sinuses, nasopharynx, throat, tonsils |
| Main treatment | Radiotherapy, usually 35-50 Gy |
| Local control | Achieved in about 85-90% |
| Main risk | Progression to multiple myeloma, more often after bone plasmacytoma |
2. Causes and risk factors
The cause is unknown. Solitary plasmacytoma is not inherited and not contagious.
As in myeloma, the tumour cells come from one abnormal plasma cell that has acquired gene changes and multiplied. Many tumours make a single type of antibody or part of an antibody, which can be measured in blood or urine as a paraprotein (M-protein) or free light chains.
| Factor | Notes |
|---|---|
| Age | Risk rises with age |
| Male sex | Men are affected more often |
| Previous MGUS | Some people have a known paraprotein before diagnosis |
2.1 How it relates to other plasma cell conditions
| Condition | Plasma cells in marrow | Lesions | Organ damage | Usual approach |
|---|---|---|---|---|
| MGUS | Under 10% | None | None | Monitoring only |
| Solitary plasmacytoma | None (or under 10% with minimal involvement) | One | None, apart from the single lesion | Radiotherapy |
| Smouldering myeloma | 10-59% | None | None | Monitoring or, for high-risk cases, early treatment |
| Multiple myeloma | Usually 10% or more | Often several | Anaemia, kidney damage, high calcium or bone lesions | Systemic treatment |
This is why careful tests of the bone marrow and the whole skeleton are needed before the diagnosis of solitary plasmacytoma can be made.
3. How does it look?
3.1 On the body
| Site | What may be seen or felt |
|---|---|
| Spine | Usually nothing visible; pain or loss of height if a vertebra collapses |
| Rib, skull or long bone | A hard swelling over the bone in some cases |
| Nose and sinuses | A soft, red or purple fleshy mass inside the nose, sometimes bleeding easily |
| Throat and tonsils | A smooth, round swelling at the back of the throat or on a tonsil |
| Neck | Enlarged lymph nodes in some extramedullary cases |
3.2 On scans
| Test | Typical finding |
|---|---|
| X-ray | A single lytic (punched-out) area in the bone, sometimes with expansion of the bone or a fracture |
| MRI | A soft-tissue mass in or around the bone; essential for spinal tumours to check for pressure on the spinal cord |
| PET-CT | A single area of high activity; also looks for hidden lesions elsewhere |
| CT of head and neck | Shows the size of extramedullary tumours in the nose or throat |
3.3 Under the microscope
| Feature | Description |
|---|---|
| Cells | Sheets of plasma cells, from mature-looking to more immature forms |
| Markers | Positive for CD138 and CD38; usually negative for CD19 and CD45; often CD56 positive |
| Clonality | All cells make the same light chain (kappa or lambda only) |
4. Symptoms
| Type | Common symptoms |
|---|---|
| Bone plasmacytoma | Bone pain at one site, often the back; a fracture after minor injury; a lump over a bone |
| Spinal plasmacytoma | Back pain; if the spinal cord or nerves are compressed: leg weakness, numbness, tingling, or problems controlling bladder or bowels |
| Extramedullary in the nose and sinuses | Blocked nose, nosebleeds, nasal discharge, facial swelling or pain |
| Extramedullary in the throat | Sore throat, difficulty swallowing, hoarse voice, snoring or a lump in the neck |
| Other extramedullary sites | Depends on the site, such as the gut, lung, skin or lymph nodes |
Unlike multiple myeloma, solitary plasmacytoma does not usually cause anaemia, kidney damage or high calcium.
4.1 Emergency symptoms
Spinal cord compression is an emergency. Seek urgent help for:
- new weakness or numbness in the legs
- difficulty walking
- loss of bladder or bowel control
- severe back pain with any of the above
5. Diagnosis
Diagnosis follows the criteria of the International Myeloma Working Group (IMWG):
| Requirement | Details |
|---|---|
| Biopsy | Proven single lesion of clonal plasma cells in bone or soft tissue |
| Bone marrow | No clonal plasma cells in a random marrow sample (or fewer than 10% in “solitary plasmacytoma with minimal marrow involvement”) |
| Imaging | No other lesions on whole-body MRI, PET-CT or low-dose CT, apart from the main tumour |
| No myeloma-related organ damage | No anaemia, high calcium or kidney damage due to plasma cells (the “CRAB” features) |
5.1 Tests used
| Test | Purpose |
|---|---|
| Biopsy of the lesion | Confirms plasmacytoma |
| Bone marrow biopsy with flow cytometry | Looks for hidden abnormal plasma cells; even small amounts raise the risk of myeloma |
| Serum and urine protein electrophoresis | Detects and measures any paraprotein |
| Serum free light chains | Measures kappa and lambda light chains |
| Blood count, calcium, kidney function | Excludes myeloma-related damage |
| Whole-body PET-CT or MRI | Excludes other lesions |
6. Treatment
6.1 Radiotherapy
Radiotherapy is the standard treatment for both types. International Lymphoma Radiation Oncology Group (ILROG) guidelines recommend:
| Situation | Typical dose |
|---|---|
| Extramedullary plasmacytoma | About 40-50 Gy; nearby lymph nodes may be included for head and neck tumours |
| Bone plasmacytoma under 5 cm | About 35-40 Gy |
| Bone plasmacytoma 5 cm or larger | About 40-50 Gy |
Treatment is usually given on weekdays over about 4-5 weeks. Each session takes only a few minutes.
6.2 Surgery
| Situation | Role of surgery |
|---|---|
| Unstable spine or fracture | Stabilisation surgery, followed by radiotherapy |
| Spinal cord compression | Urgent surgery and/or radiotherapy, with steroids |
| Small extramedullary tumour | Sometimes removed completely, then radiotherapy may be given |
6.3 Systemic treatment
| Situation | Approach |
|---|---|
| Standard solitary plasmacytoma | Chemotherapy is not routinely given after radiotherapy |
| Large tumours, high-risk features, or tumour not controlled | Myeloma-type treatment may be considered, ideally in a trial |
| Progression to multiple myeloma | Treated as myeloma |
6.4 Side effects of radiotherapy
| Site | Possible side effects |
|---|---|
| Spine or chest | Tiredness, sore throat or gullet, nausea, skin redness |
| Nose, sinuses or throat | Dry or sore mouth, taste changes, nasal crusting, dry eyes; later dry mouth and dental problems |
| Pelvis | Bowel or bladder irritation, lower blood counts |
6.5 Response after treatment
Doctors judge response using imaging and blood tests, following European expert recommendations:
| Measure | What it shows |
|---|---|
| Paraprotein and free light chains | Often fall slowly over months; complete disappearance is a good sign |
| MRI or PET-CT at 6-12 months | Reduced activity or size of the lesion; the bone may never look completely normal |
| Persistent paraprotein | Raises the risk of later myeloma and calls for closer follow-up |
| New lesions | May mean the disease has become myeloma and needs further tests |
Healing of the bone can take a long time. A remaining shadow on a scan does not always mean active disease.
7. Outlook (prognosis)
| Measure | Approximate figure |
|---|---|
| Local control after radiotherapy | About 85-90% |
| Progression to myeloma: bone plasmacytoma | About half within 10 years |
| Progression to myeloma: extramedullary plasmacytoma | Lower, roughly 10-30% |
| Minimal marrow involvement on flow cytometry | Much higher risk of progression |
| Overall survival | Median around 10 years or more, longer for extramedullary plasmacytoma |
Factors linked to a higher risk of progression include:
| Factor | Notes |
|---|---|
| Bone (rather than extramedullary) site | Main risk factor |
| Clonal plasma cells in the bone marrow | Even small amounts |
| Abnormal free light chain ratio | At diagnosis |
| Paraprotein persisting after radiotherapy | Especially if it stays at the same level for over a year |
| Tumour size 5 cm or larger | In some studies |
8. Follow-up
| What | How often |
|---|---|
| Blood tests (paraprotein, free light chains, blood count, calcium, kidney function) | Every 3-6 months for at least 5 years, then yearly |
| Imaging (MRI or PET-CT) | About 6-12 months after radiotherapy to check response, then if symptoms or blood tests change |
| Length of follow-up | Lifelong, because myeloma can develop many years later |
Report new bone pain, tiredness, frequent infections, thirst, or new lumps to your team.
9. Living with solitary plasmacytoma
| Topic | Practical advice |
|---|---|
| After spinal radiotherapy | Pain usually improves over weeks; a physiotherapist can advise on safe lifting and exercise |
| Bone health | Weight-bearing exercise, calcium and vitamin D help; your team may check bone density |
| Dental care | After head and neck radiotherapy, regular dental checks and fluoride help protect teeth |
| Work and travel | Most people return to normal activities after treatment |
| Mental wellbeing | Uncertainty about myeloma can cause anxiety; regular follow-up and open discussion with your team help |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is a solitary plasmacytoma cancer? | Yes. It is a cancer of plasma cells, but limited to one place and often controlled with radiotherapy |
| Is it the same as multiple myeloma? | No, but the two are closely related. Some people later develop myeloma |
| Will I need chemotherapy? | Usually not, unless the disease progresses to myeloma |
| Can it be cured? | Radiotherapy can cure many people, particularly with extramedullary plasmacytoma |
| Why do I need blood tests for so long? | To detect early signs of myeloma, which can then be treated promptly |
| What happens if myeloma develops? | It is usually found early through blood tests and treated with modern myeloma drugs, which control the disease for many years in most people |
| Can it come back in the same place? | Uncommonly. Radiotherapy controls the original tumour in about 9 in 10 people |
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Rajkumar, S.V. et al. (2014) ‘International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma’, The Lancet Oncology, 15(12), pp. e538-e548.
- Caers, J. et al. (2018) ‘Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel’, Journal of Hematology and Oncology, 11(1), 10.
- Soutar, R. et al. (2004) ‘Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma’, British Journal of Haematology, 124(6), pp. 717-726.
- Tsang, R.W. et al. (2018) ‘Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group’, International Journal of Radiation Oncology, Biology, Physics, 101(4), pp. 794-808.
- Dores, G.M. et al. (2009) ‘Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004’, British Journal of Haematology, 144(1), pp. 86-94.
- Dimopoulos, M.A., Moulopoulos, L.A., Maniatis, A. and Alexanian, R. (2000) ‘Solitary plasmacytoma of bone and asymptomatic multiple myeloma’, Blood, 96(6), pp. 2037-2044.
- Ozsahin, M. et al. (2006) ‘Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients’, International Journal of Radiation Oncology, Biology, Physics, 64(1), pp. 210-217.
- Knobel, D. et al. (2006) ‘Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study’, BMC Cancer, 6, 118.
- Paiva, B. et al. (2014) ‘Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma’, Blood, 124(8), pp. 1300-1303.
- Hill, Q.A. et al. (2014) ‘Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis’, Blood, 124(8), pp. 1296-1299.
- Nahi, H. et al. (2017) ‘Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register’, European Journal of Haematology, 99(3), pp. 216-222.
- Charalampous, C. et al. (2025) ‘Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes’, Blood Advances, 9(7), pp. 1559-1570.
- National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.